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Abstract
Background. As many as 50% of patients with renal cell carcinoma (RCC) will develop systemic metastases. When hepatic
metastases from RCC present in a resectable distribution, our group and other groups have previously shown that some
patients benefit from curative hepatic resection. In this report we update our own experience and summarize the literature
published to date on this topic. Methods. From 1982 to 2005, 19 patients (9 men, 10 women, median age: 50 years) with
hepatic metastases from renal cell carcinoma were treated with hepatic resection at our institution. In 14 (74%) of the 19
patients the presetnation of hepatic metastases was metachronous. Seven (37%) patients had been or were simultaneously
treated for extrahepatic metastases. The mean tumor number was 2 and the mean diameter of the largest metastasis was 73
mm. Results. Margin negative resection was achieved in 17 (89%) of 19 cases. Postoperative morbidity and mortality rates
were 32% and 5%. At a median follow-up interval of 26 months, 15 patients recurred with a mean time to recurrence of 12
months. 3-year and 5-year disease-free survivals were 25% and 25%, respectively. 3-year and 5-year overall survivals were
52% and 26%, respectively, with one patient alive 5 years following first hepatectomy. Study factors which predicated
prolonged survivals included male sex and maximum tumor diameter 5/5 cm. Discussion. The overall survival rates in our
series (3-year: 52% and 5-year: 26%) and in a complete review of the literature (3-year: 24% and 5-year:18%) indicate that
selected patients with hepatic metastases from RCC benefit from hepatic resection.
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Introduction
Malignant renal cancers occur in 3% of adults. These
tumors occur three times more frequently in men than
in women, with a peak incidence in the sixth to eighth
decades of life. The majority of renal cancers are
adenocarcinomas, and a majority of these are of
the clear cell subtype. As these tumors tend to
be aggressive and are resistant to treatment, the
prognosis of patients with advanced-stage renal cancer
is poor.
At some point in their clinical course, as many as
50% of patients diagnosed with renal cancer will
develop systemic metastases. The mechanisms for
metastases are twofold. First, these tumors tend to
spread via retroperitoneal lymphatics to distant sites,
most commonly lung, liver, lymph nodes, and bone.
Second, and unique to this malignancy, renal cancers
often demonstrate an endovenous growth pattern.
They can gain access to the vena cava via the renal
veins and develop a tumor thrombus that may extend
in the retrohepatic vena cava to the right heart
chambers.
Frequently, there is a considerable delay between
treatment of the primary renal tumor and develop-
ment of detectable systemic metastases [1]. The lungs
are the most common site of renal cancer metastases,
accounting for 75% of distant disease. Although 20%
of patients will develop hepatic metastases, in very few
cases is the liver the only site of distant spread. In fact,
the development of hepatic metastases is generally
considered a poor prognostic factor and a frequent
harbinger of more widespread disease.
Although relatively few patients present with
a metastatic disease pattern that is amenable to
a curative surgical approach, we and others have
previously identified subsets of patients who achieve
long-term survival following hepatic resection. A
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review of the literature identifies 15 reports describing
surgical treatment of hepatic metastases from renal
cancer published from 1978 to 2005 (Table I) [1/15].
Combined, these series provide survival data follow-
ing hepatic resections for renal cancer metastases in
64 patients. Importantly, the 2-year overall survival of
this cohort was 40%, which compares favorably to the
2-year overall survival of 10% for all patients who
present with metastatic renal carcinoma [16].
Also contained in these reports are analyses of
prognostic factors. In our report published in 2003,
we described a univariate analysis of the clinical
features of 14 patients with hepatic metastases from
renal cancer treated with hepatic resection [14]. In
terms of prognostic utility, the three most important
factors which predicted improved outcome were as
follows: (1) presentation of metastases /24 months
following nephrectomy, (2) metastases size B/5 cm,
and (3) R0 resection. In addition, in patients who had
recurrences in the liver following resection those who
were candidates for repeat hepatectomy experienced
a longer survival than those who were not [14].
Likewise, other series have identified a survival
advantage for patients who present with a disease-
free interval between nephrectomy and diagnosis of
their hepatic metastases /24 months and when
metastases size is B/5 cm [7].
In the current report we update our experience to
include five additional patients treated during the past
3 years. Analysis of potential prognostic factors in the
expanded cohort of 19 patients both confirms our
earlier findings and provides further insight into the
natural history of this disease.
Patients and methods
Between June 1982 and September 2005, 19 patients
(9 men, 10 women) with metastases from renal
tumors were submitted to a liver resection at our
institution. Mean patient age was 50 years with a
range from 17 to 76 years. In 16 (84%) cases, the
primary tumor histology was adenocarcinoma (clear
cell subtype), and in the remaining 3 (16%) cases the
histology was embryonal. Most patients were diag-
nosed with metastases long after the treatment of their
primary tumor, as evidenced by the mean post-
nephrectomy disease-free interval of 53 months
(range 9/137 months). Patients with extrahepatic
metastases were included if all metastatic disease
could be approached with curative intent. Seven
(37%) of the 19 patients had been treated previously
for extrahepatic metastases or presented with simul-
taneous resectable extrahepatic disease. Demo-
graphic, historical, and pathologic data for this
cohort are presented in Table II.
Statistical considerations
Disease-free and overall survival rates were calculated
by the method of Kaplan and Meier. To determine
prognostic value, study variables were compared to
survivals using log-rank tests.
Table I. Review of the literature reporting hepatic resection for renal cancer metastases.
Author Year
Number of
patients Survival
Foster [2] 1978 5 Died at 2, 6, 7, 33, and 144 months, respectively
Morrow et al. [3] 1982 1 Alive at 5 years
Thompson et al. [4] 1983 1 Data missing
Iwatsuki & Starzl [5] 1988 3 Data missing
Pontes et al. [6] 1989 2 Data missing
Tongaonkar et al. [7] 1992 1 Died at 10 months
Antoniewicz et al. [8] 1994 2 One died at 8 months, one alive at 24 months
Bennett et al. [9] 1995 4 Two died at 13 and 14 months, two alive at 21 and
32 months
Harrison et al. [10] 1997 5 Three alive at 5 years
Stief et al. [1] 1997 13 Mean survival 16 months
Fujisaki et al. [11] 1997 3 Two died at 10 and 18 months, one alive at 12 months
Kawata et al. [12] 2000 4 Two alive at 24 months
Karavias et al. [13] 2002 6 One died at 1 year, five alive at 2, 3, 5 years
Alves et al. [14] 2003 14 Median survival: 26 months; survival at 1 and 3 years,
69% and 26%, respectively; one alive at 8 years
Weitz et al. [15]* 2005 11 Two alive at 24 months
Current study$ 2005 19 Median survival: 36 months; survival at 3 and 5 years,
52% and 26%, respectively; one alive at 10 years
Total 1978/2005 75% 1-year survival: 46%
3-year survival: 24%
5-year survival: 18%
*Weitz 2005 [15] updates patients previously presented in Harrison et al. 1997 [10] (same group).
$Current study updates patients previously presented in Alves et al. 2003 [14] (same group).
%69 of 75 patients with some evaluable follow-up.
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Results
Operative details
Fory-two percent of patients presented with a solitary
hepatic metastasis and in 15 (79%) of the 19 cases the
metastases were confined to one hemiliver. The mean
size of the largest metastasis was 73 mm (range 20/
210 mm). Major hepatectomy, defined as resection of
more than 3 liver segments, was required in 14 (74%)
of the 19 operations. Anatomic resection alone was
performed in 10 cases, while 2 patients were sub-
mitted to nonanatomic resection, and the remaining 7
patients required a combined anatomic and nonana-
tomic resection approach. Margin-negative (R0) re-
sections were achieved in 17 (89%) cases.
No patients died within 30 days of hepatectomy;
however, one patient died from infectious omplica-
tions during the second postoperative month. Seven
local complications were observed in a total of six
(32%) patients but none required re-intervention.
These consisted of biliary fistula in three patients,
noninfected perihepatic fluid collection in two,
hemorrhage in one, and hepatic insufficiency in one.
General complications were observed in 4 (21%)
patients. The mean inpatient hospital stay was 13
days with a range from 6 to 27 days.
Clinical follow-up and outcomes
Recurrence and survival data were available for all 19
study patients (Table III). At a mean follow-up
interval of 26 months, five (26%) patients remained
disease-free. In the remaining 14 (74%) patients, 3
experienced hepatic recurrence only, 5 experienced
extrahepatic recurrence only, and 7 experienced both
hepatic and extrahepatic recurrence.
The time to hepatic recurrence ranged from 2 to 27
months, with a mean time of 12 months. Second
hepatectomies for hepatic recurrence were performed
in three patients, one of whom also underwent a third
hepatectomy for recurrence. The time to extrahepatic
recurrence ranged from 1 to 50 months with a mean
time of 11 months. In two patients, extrahepatic
recurrences were amenable to resection. When
combined with patients previously or simultaneously
treated for extrahepatic disease, in total nine patients
underwent at least one extrahepatic resection as part
of their treatment during the study interval. The
median, 3-year, and 5-year disease-free survival rates
following hepatectomy were 13 months, 25%, and
25%, respectively (Figure 1).
Overall survival data, which were available for all 19
patients, determined that 10 patients died during
follow-up. Nine of these 10 patients have succumbed
to metastatic renal cancer and 1 patient died of a
nononcologic cause. Of the nine patients who are alive
following initial hepatectomy, five have experienced
recurrence and four have remained disease-free. One
patient is alive 5 years following hepatic resection.
Combined, these data yield median, 3-year, and 5-
year overall survivals following initial hepatic resection
of 36 months, 52%, and 26%, respectively (Figure 2).
Analysis of prognostic factors
Univariate analysis of study variables reveals several
associations between prognostic factors and outcome
(Table IV). In comparison with female patients
(median survival/17 months), male patients
(median survival/39 months) lived longer following
hepatic resection (p/0.014). Patients between 30 and
60 years of age experienced longer survival (median
survival/120 months) than either younger (median
survival/9 months) or older (median survival/
36 months) patients. In addition, patients with
tumors 5/5 cm in diameter (median survival/39
months) tended to live longer than patients
with larger tumors (median survival/30 months)
(p/ 0.066). Patients with disease-free intervals
between treatment of the primary tumor and
diagnosis of liver metastases /2 years (median
survival/36 months) tended to live longer following
hepatectomy than patients with shorter disease-free
intervals (median survival/28 months). Finally,
patients who had recurrences and were treated with
rehepatectomy experienced a median survival
of 39 months, which was longer than the median
survival of patients who did not undergo repeat
hepatectomy (median survival/28 months).
Table II. Characteristics of 19 patients undergoing hepatic
resection for renal cancer metastases.
Factor n %
Age (years)
5/30 3 16%
30/60 9 47%
/60 7 37%
Sex
Male 9 47%
Female 10 53%
Primary tumor histology
Adenocarcinoma 16 84%
Embryonic 3 16%
Timing of metastases diagnosis
5/3 months following treatment of
primary
5/19 26%
/3 months following treatment of
primary
14/19 74%
Median time from treatment of the
primary to diagnosis of metastases
(range), months
53 (9/139)
Number of metastases
1 8 42%
2/3 10 53%
/3 1 5%
Median size (range), mm 73 (20/210)
Hepatic location
Unilobar 15 79%
Bilobar 4 21%
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Discussion
Patients with metastatic renal cell cancer have few
viable therapeutic options. Renal carcinomas and
their metastases rarely respond to traditional systemic
chemotherapy, radiotherapy, or hormone modulation
therapy. Preliminary reports suggest that approxi-
mately 10% of patients will respond to immunother-
apy composed of interleukin-2 and a higher
percentage may respond to novel anti-angiogenic
agents, but these approaches remain investigational
[17]. Although reports of prolonged survival following
hepatic resection for renal cancer metastases include
highly selected patients, the significantly improved
survival experienced by resected patients compared
with a general population with metastatic renal cancer
(5-year survival 24% vsB/10%, respectively) argues
that the treatment rather than the selection of patients
with favorable tumor biology is responsible for this
effect. Surgical extirpation of resectable renal cancer
metastases, therefore, appears to provide the only
potential for long-term survival for patients with renal
cancer liver metastases.
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Figure 1. Kaplan/Meier analysis of disease-free survival for 19
patients following hepatic resection for renal cancer metastases.
Table III. Disease-free and overall survival rates following resection of renal cancer hepatic metastases.
Parameter n %
Recurrences
None 5 26
Hepatic only 2 10
Extrahepatic only 6 32
Both hepatic and extrahepatic 6 32
Status at date of last follow-up
Alive 9 47
With recurrence 5 56
Hepatic only 0
Extrahepatic only 3
Both hepatic and extrahepatic 2
Without recurrence 4 44
Dead 10 53
With recurrence 9 90
Hepatic only 2
Extrahepatic only 3
Both hepatic and extrahepatic 4
Without recurrence 1 10
Median time from hepatectomy to hepatic recurrence (range), months 12 (2/27)
Median time from hepatectomy to extrahepatic recurrence (range), months 11 (1/50)
Median, months 3-year, % 5-year, %
Survivals
Disease-free 13 25 25
Overall 36 52 26
Total alive 5 years following first hepatectomy 1
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Figure 2. Kaplan/Meier analysis of overall survival for 19 patients
following hepatic resection for renal cancer metastases.
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Unfortunately, despite ‘R0’ hepatic resection, many
patients will have recurrences both in the liver and
at extrahepatic sites. In addition, no reliable serologic
marker of recurrence or disease burden exists.
As such, the importance of close clinical follow-up
after hepatic resection, to include axial imaging of
the thorax and abdomen, cannot be understated.
Clinical and radiographic follow-up at 3-month
intervals for the first 2 years following resection,
and subsequent follow-up at 6-month intervals is
recommended.
Our data show that over half of the post hepatect-
omy recurrences will occur within the first year. In
many cases, patients with recurrent metastases in the
liver or the lung can be submitted to repeat resection.
The finding that the subset of patients with resectable
recurrences have longer disease-free and overall
survival rates when compared to patients with un-
resectable recurrences further supports the argument
that surgery rather than favorable tumor biology is
responsible for improved outcomes.
Previously we have shown that prognostic factors
(including disease-free interval /24 months, tumor
size B/5 cm, and complete resection) can be used to
identify patients with renal cancer metastases who
most benefit from resection. Our current data, which
include analysis of one-third of the reported cases of
hepatectomy for metastatic renal cancer, show that
male patients, those with small metastases, and those
with long intervals between primary tumor therapy
and diagnosis of hepatic metastases have the best
prognosis following resection. Although recurrences
are extremely common, up to half of the patients who
share these favorable prognostic features can expect
survival intervals of 5 years following resection.
For those who do not meet these criteria, survival
rates of /2 years are common, particularly when
recurrent metastases present in a resectable pattern.
Table IV. Univariate analysis of potential prognostic variables in patients with renal cancer metastatic to the liver.
Survival rates
Factor n 1-year (%) 3-year (%) 5-year (%) Median (months) p value
Age
5/30 years 3 33 33 / 9 0.35
30/60 years 9 77 57 57 120
/60 years 7 100 53 / 36
Sex
Female 10 64 24 / 18 0.014
Male 9 88 74 49 39
Histology
Adenocarcinoma 16 79 47 31 30 0.99
Embryonic 3 67 67 / 39
Timing of metastases presentation
Metachronous (/3 months) 14 83 49 25 30 0.66
Synchronous (5/3 months) 5 57 / / /
Treatment of the primary to
diagnosis of metastases
5/24 months 11 72 45 45 28 0.67
/24 months 8 83 63 / 36
Number of metastases
1 8 67 / / 23 0.13
2/3 10 79 79 38 39
/3 1 / / / /
Size of largest metastases
5/5 cm 12 100 69 48 39 0.066
/5 cm 7 58 40 / 30
Location
Unilateral 15 70 52 17 36 0.35
Bilateral 4 100 50 / /
Prior or simultaneous extrahepatic metastases
Absent 12 82 55 37 39 0.33
Present 7 67 50 / 27
Extent of hepatectomy
Major (/3 segments) 14 71 61 30 36 0.48
Minor 5 100 / / 28
Margin of resection
R0 17 80 62 31 36 0.16
R1 2 50 / / 19
Resection of recurrent hepatic metastases
Absent 16 71 50 / 28 0.44
Present 3 100 67 33 39
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These data strongly support the recommendation
that, in the absence of effective systemic therapies,
liver resection should be offered to all patients with
liver metastases from renal cancer, provided that a
complete resection is feasible.
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